ArticleIranian biomedical journal2026
Expression of Epithelial-Mesenchymal Transition-Related Genes in Primary Brain Tumors.
Article in Iranian biomedical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gliomas are the most common malignant primary brain tumors in adults. Meningiomas, on the other hand, are benign primary brain tumors treated by surgical resection. Epithelial-to-mesenchymal transition (EMT), stemness, and leader behavior are among the most important complex processes contributing to tumor progression and aggressiveness. Thus, the evaluation of molecular targets involved in the EMT processes in primary brain tumors can help elucidate the molecular mechanisms underlying glioma aggressiveness, ultimately identifying potential areas for further research. Methods: We conducted expression analysis of zinc finger E-box homeobox 1 (ZEB1), Sry-related HMG box (SOX2), and p21 in 31 glioma (15 glioblastoma [GBM] and 16 non-GBM) and 44 meningioma samples using quantitative real-time PCR. We also compared expression levels between glioma and meningioma, as well as between GBM and non-GBM tumor samples. Results: The expression levels of SOX2 and ZEB1 showed a significant increase in gliomas compared to meningiomas (p = 0.016 and 0.017, respectively). However, p21 did not reveal any significant difference in expression between the two groups. Notably, p21 was the only gene that exhibited a significant increase in expression in GBM samples compared to non-GBM samples, with a p value of 0.027. Conclusion: Our results suggest that SOX2 and ZEB1 expression levels have a significant role in glioma progression. Interestingly, based on the elevated p21 expression level in the GBM, we also suggest that aggressive tumor features arise from distinct molecular mechanisms depending on tumor subtype, not a single universal pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.